- 中
- 繁
- EN
Beijing, Shanghai, Boston - Jacobio Pharma (1167.HK) announced the appointment of Dr. Michael Ren as the company's Vice President of Chemistry, who will participate drug discovery and chemistry research.
"Dr. Ren has extensive experience in medicinal chemistry. He will further enhance Jacobio’s early R&D capabilities and help us continue to develop the undruggable targets. We welcome his joining," said Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma.
Dr. Ren has more than 20 years of overseas work experience and previously held leadership positions at several biopharmaceutical companies in California, USA. He has many years of R&D experience in the field of small molecule drug conjugation, and has also been deeply involved in small molecule drug design and XDC. He is the co-inventor of the discovery and development of several clinical candidates.
Dr. Ren said: "I am honored to join Jacobio Pharma. My team and I will spare no effort to explore better treatment options.”
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP B 17065868-1 
京公网安备 11030102011242号